Modulation of Adipocytokines Production and Serum NEFA Level by Metformin, Glimepiride, and Sitagliptin in HFD/STZ Diabetic Rats

Table 3

Glucose homeostasis parameters of different studied groups during and at the end of the treatment period (4 weeks).

Parameter	Control	Diabetic
		Untreated	Metformin	Glimepiride	Sitagliptin
Fasting blood glucose (mg/dL)
Week ()	97.8 ± 5.9	303.6 ± 117.9^a	195.7 ± 39.8^a,b	131.75 ± 18.9^b,c	129.4 ± 34.1^b,c
Week ()	99.3 ± 5.9	369.8 ± 73.2^a	96.75 ± 8.4^b	109.7 ± 19^b	131.7 ± 38.7^b,c
Week ()	97.2 ± 4.9	353.9 ± 48.6^a	94.2 ± 9.9^b	88.5 ± 11.3^b	123.3 ± 27.3^a,b,c,d
Week ()	95.7 ± 5.5	285.1 ± 51.4^a	98.5 ± 6.7^b	87.9 ± 13.5^b	108.5 ± 14.6^b
Serum insulin (µIU/mL) at the end of the treatment period	1.8 ± 0.3	11.5 ± 0.6^a	7.27 ± 0.5^a,b	9.78 ± 0.5^a,b,c	10.1 ± 0.7^a,b,c
HOMA-IR at the end of the treatment period	0.43 ± 0.1	8.1 ± 1.4^a	1.8 ± 0.1^a,b	2.1 ± 0.3^a,b	2.7 ± 0.4^a,b,c

Values are presented as mean ± SD (). ^aSignificantly different from the control group, ^bsignificantly different from the diabetic untreated group, ^csignificantly different from the Metformin group, and ^dsignificantly different from the Glimepiride group, using ANOVA (LSD), value < 0.05.